DT10B8Z
Brachytherapy Kidney to None with Iridium 192 (Ir-192), Low Dose Rate (LDR) Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | D Radiation Therapy |
| Body System | T Urinary System |
| Operation | 1 Brachytherapy |
| Body Part | 0 Kidney |
| Approach | B Low Dose Rate (LDR) |
| Device | 8 Iridium 192 (Ir-192) |
| Qualifier | Z None |
Procedure Overview
Brachytherapy for the urinary system places a radioactive source directly inside or immediately next to a urinary structure - most often the bladder, but occasionally the ureter or urethra - so the radiation dose is delivered from within rather than passed through the body from an external machine. Small sealed sources (seeds, wires, or a temporary applicator loaded with radioactive material) are positioned using cystoscopic or image guidance, and the dose falls off sharply with distance, which lets clinicians hit a tumor hard while sparing nearby bowel, rectum, and healthy bladder wall.
It's used for muscle-invasive or recurrent bladder cancer, sometimes combined with external beam treatment and bladder-preserving surgery, and less commonly for tumors of the ureter or urethra where surgical removal would carry a high risk of losing organ function. Because the emitter sits so close to the tumor, brachytherapy can allow a higher effective dose than external radiation alone while shortening overall treatment time.
Sources may be left in temporarily (removed after the prescribed dose is delivered) or, less often for urinary sites, implanted permanently. The approach chosen depends on tumor location, stage, and whether the goal is cure, local control, or symptom relief.
Anatomy & Axis Detail
Kidney
Brachytherapy applied to the kidney places radioactive sources directly into or adjacent to renal tissue, an approach used far less often than external beam but considered in select cases, such as intraoperative placement during partial nephrectomy to treat a tumor bed with close or positive margins, or for recurrent disease where re-irradiation with external beam would exceed safe cumulative dose to surrounding structures. Delivering a source into the kidney's vascular, encapsulated parenchyma requires careful attention to bleeding risk and to the collecting system, since a misplaced source can injure the renal pelvis or ureter. This technique is typically reserved for centers with specific expertise in renal-sparing procedures, and documentation should reflect that the kidney, rather than a surrounding structure, was the direct target of source placement.
Modality Qualifier: Low Dose Rate (LDR)
Low Dose Rate (LDR) denotes brachytherapy using a source of lower activity that remains implanted or applied over an extended period, from many hours to a few days, exploiting continuous low-level irradiation for tumor control. This differs from High Dose Rate (HDR), which compresses the same general goal into brief, higher-intensity sessions, and LDR is often chosen for permanent seed implants such as certain prostate treatments.
Isotope: Iridium 192 (Ir-192)
Iridium-192 is a gamma-emitting radioisotope used almost exclusively for high-dose-rate or pulsed-dose-rate brachytherapy, delivered via remote afterloader through catheters or applicators placed in or near the tumor. It allows a shaped, temporary dose to sites like the cervix, prostate, or breast cavity, then the source is withdrawn rather than left implanted, distinguishing it from permanent seed isotopes such as I-125 or Pd-103.
Coding & Documentation
The coder needs documentation identifying the specific urinary structure treated (bladder, ureter, or urethra), since ICD-10-PCS requires a distinct body part value for each. The radiation oncology note or procedure report should state that a radioactive source was placed in or on the target tissue, not just that radiation was delivered - this is what separates brachytherapy from beam radiation or stereotactic radiosurgery.
Documentation should also support the qualifier for source type or isotope where required, and any imaging modality used for guidance if that level of specificity is captured. A common mistake is coding brachytherapy when the operative note actually describes placement of a treatment applicator during a separate session from source loading - both the insertion and the radiation delivery may need to be captured depending on facility documentation practices. Coders should also confirm the treatment site wasn't misread as an adjacent structure, since bladder and ureteral orifice procedures are described in overlapping anatomic language.